Nasal Vaccines Market Is Estimated To Witness High Growth
The Nasal Vaccines Market is estimated to be valued at US$ 416.8 million in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Nasal vaccines are pharmaceutical preparations administered through the nasal route. They induce protective immunity at the site of administration, i.e. mucous membranes of the nose and upper respiratory tract. This provides direct protection against pathogens that enter through the nasal passage. Nasal vaccines are needle-free and offer advantages such as increased efficacy, enhanced immunological response, safety, ease of self-administration and improved patient compliance.
Regional analysis
North America is currently the largest as well as the fastest growing global nasal vaccines market. Presence of major players, rising research on new nasal vaccines, and growing disease burden are driving market growth. Asia Pacific is also emerging as an attractive market owing to large patient population, improving healthcare infrastructure and increasing government support for immunization programs in countries like India and China.
Key players
Key players operating in the nasal vaccines market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd. Major players are focusing on new product approvals and developing affordable nasal vaccines for influenza, COVID-19 and other diseases affecting the respiratory tract.
Read More:
https://bloggerstrive.blogspot.com/2023/11/largest-nasal-vaccines-market-share.html
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian